Intranasal Therapy in Palliative Care
-
Published:2024-04-09
Issue:4
Volume:16
Page:519
-
ISSN:1999-4923
-
Container-title:Pharmaceutics
-
language:en
-
Short-container-title:Pharmaceutics
Author:
Ingielewicz Anna12ORCID, Szymczak Robert K.1ORCID
Affiliation:
1. Department of Emergency Medicine, Faculty of Health Science, Medical University of Gdansk, Mariana Smoluchowskiego Street 17, 80-214 Gdansk, Poland 2. Hospice Foundation, Kopernika Street 6, 80-208 Gdansk, Poland
Abstract
In recent years, the use of the intranasal route has been actively explored as a possible drug delivery method in the palliative patient population. There are reports demonstrating the effectiveness of nasally administered medications that are routinely used in patients at the end of life. The subject of this study is the intranasal drug administration among palliative patients. The aim is to summarize currently used intranasal therapies among palliative patients, determine the benefits and difficulties, and identify potential areas for future research. A review of available medical literature published between 2013 and 2023 was performed using online scientific databases. The following descriptors were used when searching for articles: “palliative”, “intranasal”, “nasal”, “end-of-life care”, “intranasal drug delivery” and “nasal drug delivery”. Out of 774 articles, 55 directly related to the topic were finally selected and thoroughly analyzed. Based on the bibliographic analysis, it was shown that drugs administered intranasally may be a good, effective, and convenient form of treatment for patients receiving palliative care, in both children and adults. This topic requires further, high-quality clinical research.
Funder
Gdańsk Medical University
Reference94 articles.
1. Zhao, J., Yang, J., Jiao, J., Wang, X., Zhao, Y., and Zhang, L. (2023). Biomedical applications of artificial exosomes for intranasal drug delivery. Front. Bioeng. Biotechnol., 11. 2. Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic;Lam;Adv. Drug Deliv. Rev.,2020 3. Jamieson, L., Harrop, E., Liossi, C., Boyce, K., Mitchell, L., Johnson, M., Jani, Y., Akinyooye, V., Skene, S.S., and Wong, I.C.K. (2022). Carer preferences of route of administration of transmucosal diamorphine and willingness to take part in a randomised controlled trial: An interview study (DIPPER). BMC Palliat. Care, 21. 4. Intranasal drug delivery: Opportunities and toxicologic challenges during drug development;Keller;Drug Deliv. Transl. Res.,2022 5. Cárdenas, G., Bobes, R.J., Fragoso, G., Pérez-Osorio, N.I., Hernández, M., Espinosa, A., Fleury, A., Flores, J., The Revival Project Consortium, and Laclette, J.P. (2022). Pharmacokinetic Study of Intranasal Dexamethasone and Methylprednisolone Compared with Intravenous Administration: Two Open-Label, Single-Dose, Two-Period, Two-Sequence, Cross-Over Study in Healthy Volunteers. Pharmaceutics, 15.
|
|